We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
7
May 2026
Experiences of cognitive problems such as memory loss or difficulty concentrating, known as 'brain fog', may not predict relapse in depression, according to a new study that has confounded researchers' expectations.
7
May 2026
A hallmark of Type 2 diabetes is the progressive loss of beta cell mass: cells in the pancreas that produce and release insulin. The endoplasmic reticulum stress response, a cellular pathway that maintains protein homeostasis, plays a critical role in beta cell function and survival, and the protein ATF6α is one of the key regulators of this stress response.
7
May 2026
Researchers investigate how birth weight determines kidney function changes following prolonged physical activity in different environmental conditions.
7
May 2026
A review in Quantitative Biology demonstrates that scientists can now reliably build and combine very large pieces of DNA, making it much easier to redesign microbes such as yeast and bacteria to act as efficient "cell factories."